Staff Profile: Raul Calvo

Raul Rolando Calvo, M.S.

Research Scientist

Division of Preclinical Innovation
Chemistry Technologies (Contractor)

National Center for Advancing Translational Sciences

National Institutes of Health

Email Raul Rolando Calvo


Raul Rolando Calvo is a research scientist in the Chemistry Technology program within NCATS’ Division of Preclinical Innovation, where he designs and synthesizes small-molecule modulators of cellular events involved in neurodegenerative diseases. Before joining NCATS as a medicinal chemist in 2013, Calvo’s efforts focused on the discovery and delivery of drugs for clinical trials in such areas as hypertension (ACE/diuretics and ACE inhibitors), osteoporosis (calcium receptor antagonists), cardiovascular disease (GpIIb/IIIa antagonists — small peptides and molecules), oncology (p53-hdm2 antagonists) and pain (TRPV1 antagonists). In 2007, Calvo received the Johnson & Johnson Innovation of the Year Award for his discovery of a TRPV1 antagonist, which is now in clinical trials.

Calvo earned a Bachelor of Science in chemistry from the State University of New York (SUNY) at Cortland in 1974 and a Master of Science in chemistry from SUNY at Stony Brook in 1982. While at Stony Brook, he worked on designing and synthesizing phospholipids to study phospholipid-protein interactions.

Research Topics

Calvo’s research aims to improve the translational process by improving understanding of fundamental processes that affect multiple diseases:

  • Modulation of TRPML channels
  • Stable analogs of DHA
  • Formulation of tocopherol derivatives
  • Modulation of autophagy
  • NPC1/Rab9 modulators
  • SixOneEya2 antagonists
  • Clearance of Huntintin aggregation in cells
  • Use of exosomes to study cellular processes and the delivery of drugs to cells